[1]邝美华,陈意珊,石亚玲.血小板与淋巴细胞比值对非小细胞肺癌预后评估的Meta分析[J].现代检验医学杂志,2018,33(03):112-116.[doi:10.3969/j.issn.1671-7414.2018.03.028]
　KUANG Mei-hua,CHEN Yi-shan,SHI Ya-ling.Prognostic Value of Platelet to Lymphocyte Ratio in Non-Small Cell Lung Cancer:a Meta-analysis[J].Journal of Modern Laboratory Medicine,2018,33(03):112-116.[doi:10.3969/j.issn.1671-7414.2018.03.028]
点击复制

血小板与淋巴细胞比值对非小细胞肺癌预后评估的Meta分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年03期
页码:
112-116
栏目:
论著
出版日期:
2018-07-17

文章信息/Info

Title:
Prognostic Value of Platelet to Lymphocyte Ratio in Non-Small Cell Lung Cancer:a Meta-analysis
文章编号:
1671-7414(2018)03-112-05
作者:
邝美华; 陈意珊; 石亚玲
广州市第八人民医院检验科,广州 510440
Author(s):
KUANG Mei-hua; CHEN Yi-shan; SHI Ya-ling
Department of Clinical Laboratory, the Eighth People's Hospital of Guangzhou,Guangzhou 510440,China
关键词:
血小板与淋巴细胞比值;  非小细胞肺癌;  预后;  Meta分析
分类号:
R734.2; R730.43
DOI:
10.3969/j.issn.1671-7414.2018.03.028
文献标志码:
A
摘要:
目的 探讨血小板与淋巴细胞比值(PLR)对非小细胞肺癌(NSCLC)患者预后的评估作用。方法 检索各中英文数据库建库至2017年10月公开发表的关于PLR与非小细胞肺癌预后关系研究的中英文文献,根据纳入与排除标准对文献进行筛选、资料提取和质量评价,筛选后的文献数据用ReviewManager5.3软件进行统计分析,将风险比(HR)与95%可信区间(95%CI)进行合并,并进行各研究间的异质性检验,根据异质性的大小决定采用固定效应模型(P>0.10,I2<50%)或随机效应模型(P<0.10,I2≥50%)进行分析。采用漏斗图进行发表偏倚分析。结果 纳入12篇符合标准的文献,共计3 720例NSCLC患者。PLR与术后总生存率(OS)的关系采用随机模型进行分析(I2=60%,P<0.01),Meta分析结果显示,高PLR组的OS明显低于低PLR组,风险比(HR=1.81),95%可信区间(95%CI:1.47～2.24,P<0.001)。进行亚组分析结果显示,在种族、治疗方法、样本量和PLR截断值等方面,高PLR组的OS明显低于低PLR组(P值均<0.05)。PLR与无病生存率/无进展生存时间(DFS/PFS)的关系采用固定效应模型进行分析(I2=21%,P=0.27),Meta分析结果显示,高PLR组的DFS/PFS明显低于低PLR组(HR=1.42,95%CI:1.22～1.65,P<0.001)。结论PLR升高的NSCLC患者预后较差,PLR可作为评估NSCLC患者预后的指标。
Abstract:
Abstract:Objective To investigate the association between platelet to lymphocyte ratio(PLR)and prognosis of non-small cell lung cancer(NSCLC).Methods All Chinese and English databases were searched for articles on association between PLR and prognosis of NSCLC publishedup to October 2017.Review Manager 5.3 was used for statistical analysis of data.Merge HR with 95% CI and conducted the heterogeneity test of the study.It was based on the size of the heterogeneity to choose a fixed effect model(P>0.10,I2 <50%)or a random effect model(P<0.10,I2≥50%).Funnel plots was used to evaluate publication bias.Results A total of 12 studies which met the inclusion criteria were included,with 3 720 NSCLC patients in total.The relationship between PLR and OS was analyzed by randomeffect model(I2=60%,P<0.01),and the Meta-analysis showed that NSCLC patients with an increased PLR had significant reductions in overall survivaltime(hazard ratio(HR)]=1.81,95%confidence interval(95%CI:1.47～2.24,P<0.001).The subgroup analysis revealed that patients with high PLR had significantly shorter OS than those with low PLR,regardless of race,treatment method,sample size,and cut-off value(all P<0.05).The relationship between PLR and DFS/PFS was analyzed by the fixed effect model(I2=21%,P=0.27),and the Meta-analysis showed that NSCLC patients with an increased PLR had significant reductions in disease-free survival or progression-free survival time(HR=1.42,95%CI:1.22～1.65,P<0.001).Conclusion High preoperative PLR was closely associated with poor prognosis of NSCLCpatients,and suggested that PLR may be a prognostic factor in NSCLC patients.

参考文献/References:

[1] Grivennikov SI,Greten FR,Immunity KM.Inflammation and cancer[J].Cell,2010,140(6):883-899.
[2] Labelle M,Becum S,Hynes RO.Direct signaling beween platelets and cancer cells induces and epithelial-mesenchymal-like transition and promotes metastasis[J].Cancer Cell,2011,20(5):576-590.
[3] Liu H,Wu Y,Wang Z,et al.Pretreatment platelet-to-lymphocyte ratio(PLR)as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer[J].J Thorac Dis,2013,5(6):783-789.
[4] Zhang T,Jiang Y,Qu X,et al.Evaluation of preoperative hematologic markers as prognostic factors and establishment of novel risk stratification in resected pN0 non-small-cell lung cancer[J].PLoS One,2014,9(10):e111494.
[5] Pinato DJ,Shiner RJ,Secki MJ,et al.Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer[J].Br J Cancer,2014,110(8),1930-1935.
[6] Wu G,Yao Y,Bai C,et al.Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients[J].Thorac Cancer,2015,6(3):275-287.
[7] 山长平,夏重升,杨 娅,等.术前外周血血小板与淋巴细胞比值对非小细胞肺癌患者预后的影响[J].中国肿瘤临床,2014,41(21):1374-1378. Shan CP,Xia CS,Yang Y,et al.Effects of preoperative blood platelet to lymphocyte ratio on prognosis of non-small cell lung cancer patients after surgical resetion[J].Chinese Tumor Clinic,2014,41(21):1374-1378.
[8] Cannon NA,Meyer J,Iyengar P,et al.Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer[J].J Thorac Oncol,2015,10(2),280-285.
[9] Kawashima M,Murakawa T,Shinozaki I,et al.Significance of the glasgowprognostic score as a prognostic indicator for lung cancer surgery[J].Interact Cardiovasc Thorac Surg,2015,21(5):637-643.
[10] Zhang H,Xia H,Zhang L,et al.Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer[J].Am J Surg,2015,210(3):526-535.
[11] Kos M,Hocazade C,Kos FT,et al.Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer[J].Wien KlinWochenschr,2016,128(17/18):635-640.
[12] Kim SH,Lee HW,Go SI,et al.Clinical significance of the preoperativeplatelet count and platelet-to-lymphocyte ratio(PLT-PLR)in patients with surgically resected non-small cell lung cancer[J].Oncotarget,2016,7(24):36198-36206.
[13] Diem S,Schmid S,Krapf M,et al.Neutrophil-to-lymphocyte ratio(NLR)and platelet-to-lymphocyte ratio(PLR)as prognostic markers in patients with non-small cell lung cancer(NSCLC)treated with nivolumab[J].Lung Cancer(Amsterdam,Netherlands),2017,111:176-181.
[14] 李 鹏,闫相涛,张国伟,等.血小板与淋巴细胞比值在非小细胞肺癌患者预后评估中的价值[J].中国实用医药,2016,11(13):5-7. Li P,Yan XT,Zhang GW,et al.Value of platelets-lymphocyte ratio in prognosis evaluation of non-small cell lung cancer patients[J].China Practical Medical,2016,11(13):5-7.
[15] Coussens LM,Werb Z.Inflammation and cancer[J].Nature,2002,420(6917):860-867.
[16] Houghton AM.Mechanistic links between COPD a-nd lung cancer[J].NatRev Cancer 2013,13(4):233-245.
[17] 张艳芳,夏 金,李醒亚.化疗前后NLR,血小板计数对评估晚期非小细胞肺癌患者预后的价值[J].国际肿瘤学杂志,2016,43(7):490-494. Zhang YF,Xia J,Li XY.Prognostic values of NLR and platelet count beforeand after chemotherapy in patients with advanced non-small cell lung cancer[J].Journal of International Oncology,2016,43(7):490-494.
[18] 李书梅,徐小莉,梁 迪,等.外周血中性粒细胞与淋巴细胞比值以及血小板与淋巴细胞比值评估胃癌患者预后的价值[J].中华肿瘤杂志,2014,36(12):910-915. Li SM,Xu XL,Liang D,et al.Prognostic value of blood neutrophil-to-lymphocyte ratio(NLR)and platelet-to-lymphocyte ratio(PLR)in patients with gastric cancer[J].Chinese Jourmal of Oncology,2014,36(12):910-915.
[19] 刘海亮,杜晓辉,孙培鸣,等.术前血小板与淋巴细胞比值对结直肠癌预后的影响[J].南方医科大学学报,2013,33(1):70-73. Liu HL,Du XH,Sun PM,et al.Preoperative platelet-lymphocyte ratio is an independent prognostic factor for resectable colorectal cancer[J].Journal of Southern Medical University,2013,33(1):70-73.
[20] 苏子剑,翟军伟,潘群雄,等.术前血小板/淋巴细胞比值与肝癌预后的关系[J].中国普通外科杂志,2016,25(1):12-18. Su ZJ,Zhai JW,Pan QX,et al.Relationship between platelet-to-lymphocyte ratio and prognosis in patients with hepatocellular carcinoma[J].Chin J Gen Surg,2016,25(1):12-18.
[21] Asano Y,Kashiwagi S,Onoda N,et al.Platelet-lymphocyte radio as a useful predictor of the therapeutic effect of neoadjuvant chemotherapy in breast cancer[J].PLoS One,2016,11(7):e0153459.
[22] Cannon NA,Neyer J,Iyengar P,et al.Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors following stereotactic radiation therapy for early-stage non-small cell lung cancer[J].Int J Radiat Oncol Biol Phys,2014,90(1):280-285.
[23] 何朝滨,林小军.中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值与TACE治疗肝癌患者预后的相关性[J].中国肿瘤临床,2017,44(6):283-288. He CB,Lin XJ.Correlation of neutrophils to lymphocyte ratio and plateletto lymphocyte ratio with prognosis of hepatocellular carcinoma patients treatedwith transarterial chemoembo-lization[J].Chinese Journal of Clinical Oncology,2017,44(6):283-288.
[24] 张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(2):83-86. Zhang L,Ren YN,Zeng TT,et al.Analysis of prognosis related factors inpatients with advanced non-small cell lung cancer[J].Journal of Modern Laboratory Medicine,2016,31(2):83-86.
[25] 彭 瑛,邓正华,温先勇.国内13种血清肿瘤标志物对肺癌诊断价值的Meta分析[J].现代检验医学杂志,2016,31(1):96-100. Peng Y,Deng ZH,Wen XY.Diagnostic value of thirteen types of serum tumormarkers for lung cancer in china:A meta-analysis[J].Journal of Modern Laboratory Medicine,2016,31(1):96-100.

相似文献/References:

[1]陈 相a,陶国华a,周 峰a,等.叉头框蛋白J2在非小细胞肺癌组织 和癌旁组织中的表达及临床意义[J].现代检验医学杂志,2016,31(03):95.[doi:10.3969/j.issn.1671-7414.2016.03.026]
　CHEN Xianga,TAO Guo-huaa,ZHOU Fenga,et al.Expression and Its Clinical Significance of Forkhead Box J2 in Non-small Cell Lung Cancer Tissues and Paracancerous Tissues[J].Journal of Modern Laboratory Medicine,2016,31(03):95.[doi:10.3969/j.issn.1671-7414.2016.03.026]
[2]刘丽燕a,陈晓丹b,杨明夏c,等.外周血异常糖链糖蛋白检测对非小细胞肺癌患者治疗监测的意义[J].现代检验医学杂志,2017,32(01):103.[doi:10.3969/j.issn.1671-7414.2017.01.028]
　LIU Li-yana,CHEN Xiao-danb,YANG Ming-xiac,et al.Significance of Tumor Abnormal Protein in Peripheral Blood in the Therapeutic Monitoring of Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2017,32(03):103.[doi:10.3969/j.issn.1671-7414.2017.01.028]
[3]张永庆a,尚立群a,苗 毅a,等.表皮生长因子受体基因突变与非小细胞肺癌病理的相关性分析[J].现代检验医学杂志,2017,32(06):78.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　ZHANG Yong-qinga,SHANG Li-quna,MIAO Yia,et al.Analysis of the Correlation between Mutations of the Epidermal Growth Factor Receptor Gene and Pathological of Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2017,32(03):78.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[4]喻 晶,李运雷,刘晓翌.非小细胞肺癌患者不同类型样本中表皮生长因子受体基因突变的差异研究[J].现代检验医学杂志,2018,33(04):31.[doi:10.3969/j.issn.1671-7414.2018.04.008]
　YU Jing,LI Yun-lei,LIU Xiao-yi.Detection of Epidermal Growth Factor Receptor Gene Mutation in Different Sample Types of 238 Patients with Non-small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(03):31.[doi:10.3969/j.issn.1671-7414.2018.04.008]
[5]林文科,吴吉芳,郑志昂.非小细胞肺癌患者血清miR-141及miR-224的表达及其临床意义[J].现代检验医学杂志,2018,33(02):46.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LIN Wen-ke,WU Ji-fang,ZHENG Zhi-ang.Expression of Serum miR-141 and miR-224 in Patients with Non-Small Cell Lung Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(03):46.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[6]朱志远,王海燕,吴 波,等.冠心病患者血小板和淋巴细胞比值与冠脉斑块稳定性及预后的相关性[J].现代检验医学杂志,2019,34(04):112.[doi:10.3969/j.issn.1671-7414.2019.04.027]
　ZHU Zhi-yuan,WANG Hai-yan,WU Bo,et al.Correlation between Ratio of Platelet to Lymphocyte with the Stability of Coronary Artery Plaque and Prognosis in Patients with Coronary Heart Disease[J].Journal of Modern Laboratory Medicine,2019,34(03):112.[doi:10.3969/j.issn.1671-7414.2019.04.027]
[7]苗留飞,杨 阳,余柏增,等.三代EGFR-TKI奥希替尼(AZD9291)耐药细胞系建立及耐药标志预测分析[J].现代检验医学杂志,2019,34(05):28.[doi:10.3969/j.issn.1671-7414.2019.05.008]
　MIAO Liu-fei,YANG Yang,YU Bai-zeng,et al.Establishment of the Third Generation of EGFR-TKI Resistant CellLine and Resistance Gene Signature[J].Journal of Modern Laboratory Medicine,2019,34(03):28.[doi:10.3969/j.issn.1671-7414.2019.05.008]
[8]张书婉,黄君华,吴文婧,等.外周血 NLR 与 PLR 对儿童完全型川崎病冠状动脉损伤的预测分析[J].现代检验医学杂志,2020,35(06):38.[doi:doi:10.3969/j.issn.1671-7414.2020.06.010]
　ZHANG Shu-wan,HUANG Jun-hua,WU Wen-jing,et al.Prediction Analysis of NLR and PLR for the Development of Coronary ArteryLesions in Patients with Complete Kawasaki Disease[J].Journal of Modern Laboratory Medicine,2020,35(03):38.[doi:doi:10.3969/j.issn.1671-7414.2020.06.010]
[9]王　旋,崔立春,党升强.非小细胞肺癌放化疗联合靶向治疗对血清肿瘤标志物、免疫功能及CyclinD3水平影响的相关研究[J].现代检验医学杂志,2021,36(04):25.[doi:10.3969/j.issn.1671-7414.2021.04.006]
　WANG Xuan,CUI Li-chun,DANG Sheng-qiang.Effects of Radiotherapy and Chemotherapy Combined with Targeted Therapy onSerum Tumor Markers, Immune Function and CyclinD3 Level inNon-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2021,36(03):25.[doi:10.3969/j.issn.1671-7414.2021.04.006]
[10]袁　丹a,郭晓敏a,刘　波b.外周血 NLR联合 PLR对动脉粥样硬化性脑梗死诊断及预测斑块稳定性的价值研究[J].现代检验医学杂志,2022,37(01):199.[doi:10.3969/j.issn.1671-7414.2022.01.041]
　YUAN Dana,GUO Xiao-mina,LIU Bob.Value of Peripheral Blood NLR Combined with PLR in Diagnosis of Atherosclerotic Cerebral Infarction and Prediction ofPlaque Stability[J].Journal of Modern Laboratory Medicine,2022,37(03):199.[doi:10.3969/j.issn.1671-7414.2022.01.041]

备注/Memo

备注/Memo:
作者简介:邝美华(1987-),女,本科,检验科技师,主要从事临床免疫检验工作,E-mail:meihuaxiaobai@163.com。 通讯作者:石亚玲,主任技师,主要从事临床免疫检验研究,E-mail:13798066558@126.com。
更新日期/Last Update: 2018-04-16